Skip to content

Pfizer

Active Risk: low
Public limited companyfounded 195472 yrs activePleinlaan 17, 1050 Elsene, BelgiumKBO/BCE: BE 0401.994.823
Summary

Pfizer has been active since 1954 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show a net result of €3.7m. Equity remains stable across the filed fiscal years (±2.2% per year). Its net result ranks better than 94% of 4914 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (low).

Checked score

No current score
Insufficient figures
A score requires measurable solvency, liquidity and profitability. Missing figures are not a judgement about the company.
Axes · tick = 2024
Profitability57▼-14
Solvency-
Growth61▼-18
Track record100
Bankruptcy probability, 12 months
0.5% Low
0%0.5%1.5%4%10%≥ 25%
Credit check for your own amount and term

Open the credit simulator : see how the verdict changes with amount, term and advance.

Signals

Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 72 years 0 80 y
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
raises risk · Multiple establishment units
Several establishment units mean more fixed costs, and such companies fail more often than a company with one establishment.
KBO · establishment units
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Return on assets
1%
Age of the figures
10 mo
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 46
Relative position
BE, all sectors
reference
Wholesale trade (NACE 46)
about 21% more bankruptcies
← fewer bankruptcies more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 30-11-2025 was due by 30-06-2026 and was filed on 02-06-2026, 28 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
28 d early
2024
38 d early
2023
40 d early
2022
38 d early
2021
29 d early
2020
30 d early
2019
1 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 29 days before the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 30-11-2026 and is due by 30-06-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
27-09-2026 today30-11-2026 close30-06-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

On 1 February 1954, Pfizer was incorporated.1 In 2005 the registered office moved to Bruxelles.2 The capital was increased 3 times between 2010 and 2020, most recently to EUR 40 million.345 Wyeth Pharmaceuticals and PF OFG Belgium were merged into the company between 2010 and 2019.34 Of the 3 current board members, Laurence Einsweiler has served longest, since 2013.6 Revenue went from EUR 221 million in 2019 to EUR 358 million in 2025 and headcount from 319 to 297 full-time equivalents.7

  1. 1Crossroads Bank for Enterprises
  2. 2Belgian State Gazette, 12-07-2005
  3. 3Belgian State Gazette, 27-07-2010
  4. 4Belgian State Gazette, 19-03-2019
  5. 5Belgian State Gazette, 20-05-2020
  6. 6Belgian State Gazette, 25-09-2013
  7. 7National Bank, annual accounts 2019 and 2025

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, full schema

Turnover
€358.3m▲ 6.5%
2024 · €336.5m
EBIT margin
4.2%▼ 6.5pp
2024 · 10.8%
Net result
€3.7m▼ 84.2%
2024 · €23.2m
Working capital
€141.2m▲ 11.9%
2024 · €126.1m
Trend over the years

Click a name to add, emphasise or remove a line.

Every figure with its change against the fiscal year before
favourable unfavourable
Line20212022202320242025
Turnover€469.5m▲ 95.5%€548.2m▲ 16.8%€349.4m▼ 36.3%€336.5m▼ 3.7%€358.3m▲ 6.5%
Operating result€27.1m▲ 83.9%€29.8m▲ 10.1%€20.7m▼ 30.7%€36.2m▲ 75.2%€15.1m▼ 58.2%
Net result€19.5m▲ 102%€21.6m▲ 10.7%€12.9m▼ 40.3%€23.2m▲ 79.7%€3.7m▼ 84.2%
EBIT margin5.8%▼ 0.4pp5.4%▼ 0.3pp5.9%▲ 0.5pp10.8%▲ 4.8pp4.2%▼ 6.5pp
Equity€118.8m▲ 19.7%€90.4m▼ 23.9%
Total assets€254.7m▲ 31.2%€285.3m▲ 12.0%€383.4m▲ 34.4%€474.6m▲ 23.8%€377.4m▼ 20.5%
Debt€132.2m▲ 43.2%€183.5m▲ 38.8%€275.7m▲ 50.3%€346.0m▲ 25.5%€226.6m▼ 34.5%
Working capital€114.5m▲ 21.8%€91.4m▼ 20.2%€123.1m▲ 34.7%€126.1m▲ 2.5%€141.2m▲ 11.9%
Staff (FTE)333.4▲ 1.0%336.3▲ 0.9%338.2▲ 0.6%323▼ 4.5%297▼ 8.0%
Result per fiscal year
Operating resultNet result
€0€10.0m€20.0m€30.0m€40.0mOperating result 2021: €27.1m€27.1mNet result 2021: €19.5m€19.5mOperating result 2022: €29.8m€29.8mNet result 2022: €21.6m€21.6mOperating result 2023: €20.7m€20.7mNet result 2023: €12.9m€12.9mOperating result 2024: €36.2m€36.2mNet result 2024: €23.2m€23.2mOperating result 2025: €15.1m€15.1mNet result 2025: €3.7m€3.7m20212022202320242025€0€10m€20m€30m€40mOperating result 2023: €20.7m€21mNet result 2023: €12.9m€13mOperating result 2024: €36.2m€36mNet result 2024: €23.2m€23mOperating result 2025: €15.1m€15mNet result 2025: €3.7m€3.7m202320242025
The operating result falls in 2025; 2025 is 58% below 2024 and is the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €377.4m
Fixed assets €11.4m ▲ 12.9%
Current assets €365.9m ▼ 21.2%
Key figures and ratios
2025 value · change against 2024
EBITDA
€16.2m▼
2024 · €37.3m
Cash flow
€4.7m▼
2024 · €24.2m
Current ratio
1.63▲
2024 · 1.37
Quick ratio
0.85▲
2024 · 0.82
ROA
1.0%▼
2024 · 4.9%
Interest coverage
5.67▼
2024 · 8.59
Debt ≤ 1 year
€224.7m▼
2024 · €338.4m
Income taxes
€9.1m▼
2024 · €9.5m
Staff costs
€53.9m▼
2024 · €76.4m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 79 lines
Balance sheet Code20242025
Assets
Total assets20/58€474.6m€377.4m▼
Fixed assets21/28€10.1m€11.4m▲
Tangible fixed assets22/27€5.1m€6.4m▲
Plant, machinery and equipment23€524,967€402,022▼
Furniture and vehicles24€924,462€695,213▼
Other tangible fixed assets26€3.5m€3.0m▼
Assets under construction and advance payments27€87,279€2.3m▲
Financial fixed assets28€5.1m€5.1m▲
Affiliated companies280/1€4.2m€4.2m=
Participating interests280€4.2m€4.2m=
Other financial fixed assets284/8€808,456€822,706▲
Amounts receivable and cash guarantees285/8€808,456€822,706▲
Current assets29/58€464.5m€365.9m▼
Stocks and contracts in progress3€188.0m€175.1m▼
Stocks30/36€188.0m€175.1m▼
Goods purchased for resale34€188.0m€175.1m▼
Amounts receivable within one year40/41€165.6m€166.0m▲
Trade receivables40€161.0m€123.7m▼
Other amounts receivable41€4.6m€42.3m▲
Current investments50/53€87.1m€18,311▼
Other investments51/53€87.1m€18,311▼
Cash at bank and in hand54/58€21.3m€23.9m▲
Deferred charges and accrued income490/1€2.5m€909,253▼
Equity and liabilities
Total equity and liabilities10/49€474.6m€377.4m▼
Contributions10/11€40.8m€40.8m=
Capital10€39.7m€39.7m=
Issued capital100€39.7m€39.7m=
Outside capital11€1.1m€1.1m=
Share premium1100/10€1.1m€1.1m=
Reserves13€8.0m€8.0m=
Non-distributable reserves130/1€4.0m€4.0m=
Legal reserve130€4.0m€4.0m=
Other1319€23,251€23,251=
Tax-exempt reserves132€4.0m€4.0m=
Distributable reserves133€14,909€14,909=
Profit (loss) carried forward14€77.7m€81.4m▲
Provisions for liabilities and charges160/5€2.1m€20.5m▲
Other liabilities and charges164/5€2.1m€20.5m▲
Amounts payable17/49€346.0m€226.6m▼
Amounts payable within one year42/48€338.4m€224.7m▼
Financial debts43€24,443€162.9m▲
Credit institutions430/8€24,443€827,285▲
Other loans439-€162.0m
Trade debts44€75.9m€34.0m▼
Suppliers440/4€75.9m€34.0m▼
Taxes, remuneration and social security45€255.6m€23.3m▼
Taxes450/3€237.6m€7.0m▼
Remuneration and social security454/9€18.0m€16.3m▼
Other amounts payable47/48€6.9m€4.5m▼
Accrued charges and deferred income492/3€7.7m€1.9m▼
Income statement Code20242025
Operating income70/76A€392.6m€414.1m▲
Turnover70€336.5m€358.3m▲
Other operating income74€56.1m€55.8m▼
Operating charges60/66A€356.3m€399.0m▲
Goods for resale, raw materials and consumables60€222.0m€274.6m▲
Change in stocks: decrease (increase)609-€23.7m€17.3m▲
Services and other goods61€36.9m€34.7m▼
Remuneration, social security and pensions62€76.4m€53.9m▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€1.0m€1.0m▼
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€5.8m-€4.4m▼
Provisions for liabilities and charges: additions (uses and reversals)635/8-€2.3m€18.4m▲
Other operating charges640/8€16.5m€20.8m▲
Operating profit (loss)9901€36.2m€15.1m▼
Recurring financial income75€1.3m€1.3m▼
Income from current assets751€1.1m€744,694▼
Other financial income752/9€252,313€564,226▲
Financial charges65/66B€4.9m€3.7m▼
Recurring financial charges65€4.9m€3.7m▼
Debt charges650€4.3m€2.8m▼
Other financial charges652/9€563,236€808,000▲
Profit (loss) for the period before taxes9903€32.6m€12.8m▼
Income taxes67/77€9.5m€9.1m▼
Taxes670/3€9.5m€9.1m▼
Profit (loss) for the period9904€23.2m€3.7m▼
Profit (loss) for the period to be appropriated9905€23.2m€3.7m▼
Appropriation of the result
Profit (loss) to be appropriated9906€77.7m€81.4m▲
Profit (loss) brought forward from the previous period14P€54.5m€77.7m▲
From reserves792€1-
Social balance
Average headcount (FTE)9087323.0297.0▼

The notes to these accounts (63 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20212022202320242025Change
Operating income70/76A€543.0m€632.9m€413.6m€392.6m€414.1m▲ 5.5%
Turnover70€469.5m€548.2m€349.4m€336.5m€358.3m▲ 6.5%
Other operating income74€71.9m€84.7m€64.2m€56.1m€55.8m▼ 0.6%
Non-recurring operating income76A€1.6m-----
Operating charges60/66A€515.9m€603.1m€392.9m€356.3m€399.0m▲ 12.0%
Goods for resale, raw materials and consumables60€401.7m€467.8m€275.1m€222.0m€274.6m▲ 23.7%
Change in stocks: decrease (increase)609€3.8m-€40.0m-€42.2m-€23.7m€17.3m▲ 173%
Services and other goods61€44.4m€47.0m€42.9m€36.9m€34.7m▼ 6.0%
Remuneration, social security and pensions62€56.5m€66.1m€64.9m€76.4m€53.9m▼ 29.4%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€1.2m€1.1m€983,318€1.0m€1.0m▼ 3.4%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4-€1.8m-€302,541€2.9m€5.8m-€4.4m▼ 176%
Provisions for liabilities and charges: additions (uses and reversals)635/8€1.1m€7.8m-€7.0m-€2.3m€18.4m▲ 917%
Other operating charges640/8€12.8m€13.5m€13.2m€16.5m€20.8m▲ 26.1%
Operating profit (loss)9901€27.1m€29.8m€20.7m€36.2m€15.1m▼ 58.2%
Recurring financial income75€219,910€798,519€1.2m€1.3m€1.3m▼ 1.7%
Income from current assets751€13,572€136,816€710,096€1.1m€744,694▼ 31.0%
Other financial income752/9€206,338€661,703€442,999€252,313€564,226▲ 124%
Financial charges65/66B€303,062€1.0m€3.8m€4.9m€3.7m▼ 25.4%
Recurring financial charges65€303,062€1.0m€3.8m€4.9m€3.7m▼ 25.4%
Debt charges650€126,527€315,003€3.3m€4.3m€2.8m▼ 34.3%
Other financial charges652/9€176,535€694,578€548,100€563,236€808,000▲ 43.5%
Profit (loss) for the period before taxes9903€27.0m€29.6m€18.0m€32.6m€12.8m▼ 60.8%
Income taxes67/77€7.5m€8.0m€5.1m€9.5m€9.1m▼ 3.5%
Taxes670/3€7.5m€8.1m€5.1m€9.5m€9.1m▼ 3.5%
Tax adjustments and reversals of tax provisions77€9,366€114,849----
Profit (loss) for the period9904€19.5m€21.6m€12.9m€23.2m€3.7m▼ 84.2%
Profit (loss) for the period to be appropriated9905€19.5m€21.6m€12.9m€23.2m€3.7m▼ 84.2%
Line20212022202320242025Change
Assets
Total assets20/58€254.7m€285.3m€383.4m€474.6m€377.4m▼ 20.5%
Fixed assets21/28€10.1m€11.2m€11.1m€10.1m€11.4m▲ 12.9%
Tangible fixed assets22/27€5.3m€6.4m€6.0m€5.1m€6.4m▲ 25.5%
Plant, machinery and equipment23€766,822€731,499€698,318€524,967€402,022▼ 23.4%
Furniture and vehicles24€319,344€565,140€630,594€924,462€695,213▼ 24.8%
Other tangible fixed assets26€4.1m€4.3m€4.1m€3.5m€3.0m▼ 15.6%
Assets under construction and advance payments27€77,279€782,903€620,634€87,279€2.3m▲ 2,518%
Financial fixed assets28€4.8m€4.8m€5.1m€5.1m€5.1m▲ 0.3%
Affiliated companies280/1€4.2m€4.2m€4.2m€4.2m€4.2m=
Participating interests280€4.2m€4.2m€4.2m€4.2m€4.2m=
Other financial fixed assets284/8€548,694€570,504€829,227€808,456€822,706▲ 1.8%
Amounts receivable and cash guarantees285/8€548,694€570,504€829,227€808,456€822,706▲ 1.8%
Current assets29/58€244.6m€274.0m€372.3m€464.5m€365.9m▼ 21.2%
Stocks and contracts in progress3€90.4m€130.7m€170.1m€188.0m€175.1m▼ 6.9%
Stocks30/36€90.4m€130.7m€170.1m€188.0m€175.1m▼ 6.9%
Goods purchased for resale34€90.4m€130.7m€170.1m€188.0m€175.1m▼ 6.9%
Amounts receivable within one year40/41€111.3m€142.4m€179.8m€165.6m€166.0m▲ 0.2%
Trade receivables40€109.6m€136.3m€171.0m€161.0m€123.7m▼ 23.2%
Other amounts receivable41€1.7m€6.1m€8.8m€4.6m€42.3m▲ 823%
Current investments50/53--€63,697€87.1m€18,311▼ 100.0%
Other investments51/53--€63,697€87.1m€18,311▼ 100.0%
Cash at bank and in hand54/58€40.7m€724,690€21.9m€21.3m€23.9m▲ 12.1%
Deferred charges and accrued income490/1€2.2m€201,752€426,728€2.5m€909,253▼ 63.8%
Equity and liabilities
Total equity and liabilities10/49€254.7m€285.3m€383.4m€474.6m€377.4m▼ 20.5%
Equity10/15€118.8m€90.4m----
Contributions10/11€40.8m€40.8m€40.8m€40.8m€40.8m=
Capital10€39.7m€39.7m€39.7m€39.7m€39.7m=
Issued capital100€39.7m€39.7m€39.7m€39.7m€39.7m=
Outside capital11€1.1m€1.1m€1.1m€1.1m€1.1m=
Share premium1100/10€1.1m€1.1m€1.1m€1.1m€1.1m=
Reserves13€8.0m€8.0m€8.0m€8.0m€8.0m=
Non-distributable reserves130/1€4.0m€4.0m€4.0m€4.0m€4.0m=
Legal reserve130€4.0m€4.0m€4.0m€4.0m€4.0m=
Other1319€23,251€23,251€23,251€23,251€23,251=
Tax-exempt reserves132€4.0m€4.0m€4.0m€4.0m€4.0m=
Distributable reserves133€14,909€14,909€14,909€14,909€14,909=
Profit (loss) carried forward14€70.0m€41.6m€54.5m€77.7m€81.4m▲ 4.7%
Provisions and deferred taxes16€3.6m€11.4m----
Provisions for liabilities and charges160/5€3.6m€11.4m€4.4m€2.1m€20.5m▲ 876%
Pensions and similar obligations160-€3.7m----
Other liabilities and charges164/5€3.6m€7.6m€4.4m€2.1m€20.5m▲ 876%
Amounts payable17/49€132.2m€183.5m€275.7m€346.0m€226.6m▼ 34.5%
Amounts payable within one year42/48€130.1m€182.6m€249.2m€338.4m€224.7m▼ 33.6%
Financial debts43-€81.3m€146.6m€24,443€162.9m▲ 666,233%
Credit institutions430/8---€24,443€827,285▲ 3,285%
Other loans439-€81.3m€146.6m-€162.0m-
Trade debts44€66.4m€26.4m€5.9m€75.9m€34.0m▼ 55.1%
Suppliers440/4€66.4m€26.4m€5.9m€75.9m€34.0m▼ 55.1%
Taxes, remuneration and social security45€63.7m€75.0m€76.4m€255.6m€23.3m▼ 90.9%
Taxes450/3€46.9m€52.4m€60.9m€237.6m€7.0m▼ 97.1%
Remuneration and social security454/9€16.8m€22.5m€15.6m€18.0m€16.3m▼ 9.3%
Other amounts payable47/48€22,075-€20.3m€6.9m€4.5m▼ 35.0%
Accrued charges and deferred income492/3€2.1m€828,249€26.5m€7.7m€1.9m▼ 74.7%
Line20212022202320242025Change
Profit (loss) for the period9904€19.5m€21.6m€12.9m€23.2m€3.7m▼ 84.2%
+ Depreciation and write-downs630€1.2m€1.1m€983,318€1.0m€1.0m▼ 3.4%
Operating cash flow (approximation)€20.7m€22.7m€13.9m€24.2m€4.7m▼ 80.7%
Investment in fixed assets (approximation)--€2.3m-€824,629-€90,096-€2.3m▼ 2,470%
Change in cash--€40.0m€21.2m-€591,241€2.6m▲ 535%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 30-06-2027
2026
04-08
State Gazette act Resignations: Guy Van den Meersche (director) and Anne De Backer (director)
Appointment: Kathleen Commers (director) · Director discharge9 facts ▸
  • General meeting, 01-07-2026
  • Director resignation, Guy Van den Meersche (director)
  • Director resignation, Anne De Backer (director)
  • Director discharge, Guy Van den Meersche
  • Director discharge, Anne De Backer
  • Director appointment, Kathleen Commers (director)
  • Board composition, Réginald Decraene (director)
  • Board composition, Laurence Einsweiler (director)
  • Board composition, Kathleen Commers (director)
02-06
NBB filing Annual accounts filed
fiscal year 2025 · full schema
19-01
State Gazette act Resignation: David Lepoittevin (director)
Appointment: Réginald Decraene (director) · Director discharge · Mandate compensation8 facts ▸
  • General meeting, 20/11/2025
  • Board meeting, 24/11/2025
  • Director resignation, David Lepoittevin (director)
  • Director resignation, David Lepoittevin (managing director)
  • Director discharge, David Lepoittevin
  • Director appointment, Réginald Decraene (director)
  • Mandate compensation, Réginald Decraene
  • Director appointment, Réginald Decraene (managing director)
2025
30-11
Financial Weakest financial yearnet €3.7m ▼84.2%
Net result drops to €3.7m, the lowest in the series.
26-06
State Gazette act Reappointment: Laurence Einsweiler (director)
Appointment: KPMG Réviseurs d'Entreprises SRL (statutory auditor) · Mandate compensation4 facts ▸
  • General meeting, 21 mai 2025
  • Director reappointment, Laurence Einsweiler (director)
  • Mandate compensation, Laurence Einsweiler
  • Auditor appointment, KPMG Réviseurs d'Entreprises SRL (statutory auditor)
23-05
NBB filing Annual accounts filed
fiscal year 2024 · full schema
21-03
State Gazette act Resignation: An Van Gerven (managing director)
Appointments: David Lepoittevin (director) and KPMG Bedrijfsrevisoren (statutory auditor) · Permanent representative: Steven Veyt · Director discharge19 facts ▸
  • General meeting, 17/02/2025
  • Board meeting, 18/02/2025
  • Director resignation, An Van Gerven (managing director)
  • Director discharge, An Van Gerven
  • Director appointment, David Lepoittevin (director)
  • Mandate compensation, David Lepoittevin
  • Permanent representative, Steven Veyt
  • Auditor appointment, KPMG Bedrijfsrevisoren (statutory auditor)
  • Director resignation, An Van Gerven (délégation de la gestion journalière)
  • Director appointment, David Lepoittevin (managing director)
  • Power of attorney, Catherine Pélissier
  • Power of attorney, Dimitri Galle
  • +7 further facts in this act
2024
30-11
Financial Highest result since 2018net €23.2m ▲79.7%
Operating result €36.2m, net result €23.2m, both a record.
21-05
NBB filing Annual accounts filed
fiscal year 2023 · full schema
2023
24-05
State Gazette act Resignations & appointments
Officer change · Power of attorney · Mandate term15 facts ▸
  • Board meeting, 26/04/2023
  • Board meeting, 27/04/2023
  • Officer change
  • Power of attorney, DLA Piper UK LLP
  • Power of attorney, Philippe Legrand
  • Power of attorney, Véronique Gobiet
  • Power of attorney, Micheline Vrancken
  • Power of attorney, Nathalie Gonnissen
  • Power of attorney, Catherine Pélissier
  • Power of attorney, Ana Moreno Morales de Setien
  • Power of attorney, Dimitri Galle
  • Power of attorney, Machiel De Dauw
  • +3 further facts in this act
23-05
NBB filing Annual accounts filed
fiscal year 2022 · full schema
2022
06-12
State Gazette act Resignation: Karel van de Sompel (director)
Appointment: An Van Gerven (director) · Mandate compensation · Power of attorney8 facts ▸
  • General meeting, 03/10/2022
  • Director resignation, Karel van de Sompel (director)
  • Director appointment, An Van Gerven (director)
  • Mandate compensation, An Van Gerven
  • Board meeting, 03/10/2022
  • Director resignation, Karel van de Sompel (managing director)
  • Power of attorney, Karel van de Sompel
  • Director appointment, An Van Gerven (managing director)
Show earlier events
19-08
State Gazette act Appointment: KPMG Réviseurs d'Entreprises SRL (statutory auditor)
2 facts ▸
  • General meeting, 10/06/2022
  • Auditor appointment, KPMG Réviseurs d'Entreprises SRL (statutory auditor)
01-06
NBB filing Annual accounts filed
fiscal year 2021 · full schema
2021
30-11
Financial Equity above €100mEq €118.8m ▲19.7%
4 profitable years in a row build equity to €118.8m.
26-08
State Gazette act Resignation: Didier Vinel (director)
Appointments: Guy Van den Meersche (director) and Anne De Backer (director) · Mandate compensation6 facts ▸
  • General meeting, 18/05/2021
  • Director resignation, Didier Vinel (director)
  • Director appointment, Guy Van den Meersche (director)
  • Director appointment, Anne De Backer (director)
  • Mandate compensation, Guy Van den Meersche
  • Mandate compensation, Anne De Backer
03-08
State Gazette act Resignation: Didier Vinel (director)
Appointments: Guy Van den Meersche (director) and Anne De Backer (director) · Mandate compensation · Mandate acceptance8 facts ▸
  • General meeting, 18/05/2021
  • Director resignation, Didier Vinel (director)
  • Director appointment, Guy Van den Meersche (director)
  • Director appointment, Anne De Backer (director)
  • Mandate compensation, Guy Van den Meersche
  • Mandate compensation, Anne De Backer
  • Mandate acceptance, ja
  • Mandate acceptance, ja
31-05
NBB filing Annual accounts filed
fiscal year 2020 · full schema
2020
29-06
NBB filing Annual accounts filed
fiscal year 2019 · full schema
20-05
State Gazette act Capital & shares · Statutes amendment
Capital increase · Capital · Net-asset statement6 facts ▸
  • General meeting, 30/04/2020
  • Capital increase, €10.750.006,46
  • Capital, €39.688.620,47
  • Statutes amendment
  • Net-asset statement, 25/02/2019
  • Power of attorney, DLA Piper
11-03
State Gazette act Capital & shares
Capital2 facts ▸
  • General meeting, 21/01/2020
  • Capital, €50.000.000
19-02
State Gazette act Miscellaneous
Dividend distribution2 facts ▸
  • General meeting, 21/01/2020
  • Dividend distribution, 50.000.000 EUR
2019
30-11
Financial Equity above €100mEq €139.7m ▲55.6%
2 profitable years in a row build equity to €139.7m.
10-07
State Gazette act Miscellaneous
Share transfer1 fact ▸
  • Share transfer, Pfizer International Markets B.V.
18-06
State Gazette act Reappointments: Karel Van De Sompel, Didier Vinel and Laurence Einweller
Appointment: KPMG Réviseurs d'Entreprises (statutory auditor) · Permanent representative: Olivier Declercq · Mandate compensation9 facts ▸
  • General meeting, 15/05/2019
  • Director reappointment, Karel Van De Sompel (director)
  • Director reappointment, Didier Vinel (director)
  • Director reappointment, Laurence Einweller (director)
  • Mandate compensation, Karel Van De Sompel
  • Mandate compensation, Didier Vinel
  • Mandate compensation, Laurence Einweller
  • Auditor appointment, KPMG Réviseurs d'Entreprises (statutory auditor)
  • Permanent representative, Olivier Declercq
22-05
NBB filing Annual accounts filed
fiscal year 2018 · full schema
03-04
State Gazette act Resignations & appointments
Power of attorney5 facts ▸
  • Board meeting, 11/03/2019
  • Power of attorney, Ann Matton (mandataire)
  • Power of attorney, Isabel Vanderriest (mandataire)
  • Power of attorney, Annelies Inzé (mandataire)
  • Power of attorney, Rembert Van De Sande (mandataire)
19-03
State Gazette act Capital & shares · Restructuring
Merger · Accounting effect · Capital increase8 facts ▸
  • General meeting, 22/02/2019
  • Merger, 25/02/2019
  • Accounting effect, 25/02/2019
  • Capital increase, €10.666.355
  • Share issue, 66895
  • Capital, €39.604.969,01
  • Power of attorney, DLA Piper
  • Power of attorney, Ernst & Young Réviseurs d'Entreprises
05-03
State Gazette act Resignations & appointments
Power of attorney8 facts ▸
  • Board meeting, 05/02/2019
  • Power of attorney, Catherine Pélissier
  • Power of attorney, An Van Gerven
  • Power of attorney, Véronique Gobiet
  • Power of attorney, Micheline Vrancken
  • Power of attorney, Nathalie Gonnissen
  • Power of attorney, Catherine Pélissier
  • Power of attorney, Ana Moreno De Setien
22-01
State Gazette act Restructuring
Merger · Accounting effect · Share issue10 facts ▸
  • Merger, absorption, scission partielle de Pfizer PFE au bénéfice de PF OFG
  • Accounting effect, 25/02/2019
  • Board meeting, 09/01/2019
  • Share issue, actions nominatives ordinaires, sans mention de valeur nominale, 66895
  • Mandate compensation, KPMG Réviseurs d'Entreprises BCVBA
  • Market value, 56.018.500 EUR
  • Market value, 125.000.000 EUR
  • Number of shares, 5617015935
  • Number of shares, 149271
  • Valuation date, 07/01/2019
2018
30-05
NBB filing Annual accounts filed
fiscal year 2017 · full schema
2017
06-12
State Gazette act Resignations & appointments
Power of attorney2 facts ▸
  • Board meeting, 10/11/2017
  • Power of attorney, Anne De Backer (hr mos lead)
14-11
State Gazette act Permanent representatives: Olivier Declercq and Patrick Simons
3 facts ▸
  • Board meeting, 29/09/2017
  • Permanent representative, Olivier Declercq
  • Permanent representative, Patrick Simons
28-06
State Gazette act Resignations & appointments
Power of attorney2 facts ▸
  • Board meeting, 08/06/2017
  • Power of attorney, Stéphane Komar
09-06
NBB filing Annual accounts filed
fiscal year 2016 · full schema
2016
27-06
State Gazette act Appointment: SCRL Klynveld Peat Marwick Goerdeler - Réviseurs d'entreprise (KPMG) (statutory auditor)
2 facts ▸
  • General meeting, 18/05/2016
  • Auditor appointment, SCRL Klynveld Peat Marwick Goerdeler - Réviseurs d'entreprise (KPMG) (statutory auditor)
17-02
State Gazette act Resignations & appointments
Power of attorney5 facts ▸
  • Board meeting, 25/01/2016
  • Power of attorney, Jorgen Schaffers
  • Power of attorney, Dominique Winand
  • Power of attorney, Catherine Pélissier
  • Power of attorney, An Van Gerverı
2015
29-12
State Gazette act Restructuring
Capital decrease · Capital · Net-asset statement6 facts ▸
  • General meeting, 30/11/2015
  • Capital decrease, €16.975.840,99
  • Capital, €28.938.614,01
  • Net-asset statement, 30/11/2014
  • Statutes amendment
  • Demerger, 30/11/2015
24-11
State Gazette act Capital & shares
Dividend distribution4 facts ▸
  • General meeting, 05/11/2015
  • Dividend distribution, dividende intermédiaire
  • Dividend distribution, dividende intermédiaire
  • Dividend distribution, dividende intermédiaire total
15-10
State Gazette act Reappointment: Karel Van De Sompel (managing director)
2 facts ▸
  • Board meeting, 24/09/2015
  • Director reappointment, Karel Van De Sompel (managing director)
01-07
State Gazette act Reappointments: Karel Van De Sompel (director) and Didier Vinel (director)
Mandate compensation5 facts ▸
  • General meeting, 20/05/2015
  • Director reappointment, Karel Van De Sompel (director)
  • Mandate compensation, Karel Van De Sompel
  • Director reappointment, Didier Vinel (director)
  • Mandate compensation, Didier Vinel
2014
30-12
State Gazette act Capital & shares · Statutes amendment · Restructuring
Demerger · Accounting effect · Net-asset statement13 facts ▸
  • General meeting, 01/12/2014
  • Board meeting, 28/11/2014
  • Demerger, GEP Business Scindé (Global Established Pharmaceutical Business)
  • Accounting effect, 01/12/2014
  • Net-asset statement, 01/12/2014
  • Capital decrease, €18.489.777,79
  • Capital, €27.424.677,21
  • Share issue, parts sociales nominatives ordinaires, 67000000
  • Power of attorney, DLA Piper UK LLP
  • Statutes amendment
  • Exchange ratio, chaque action de Pfizer donnant droit à 448,848068278 parts sociales de Pfizer PFE
  • Equity reduction, 40.423.415,93, EUR
  • +1 further facts in this act
27-10
State Gazette act Restructuring
Demerger · Accounting effect · Share issue4 facts ▸
  • Demerger
  • Accounting effect, 01/12/2014
  • Share issue, nouvelles parts sociales de Pfizer PFE émises au profit des actionnaires de Pfizer
  • Power of attorney, DLA Piper UK LLP
20-06
State Gazette act Appointment: SCRL Klynveld Peat Marwick Goerdeler - Réviseurs d'entreprise (KPMG) (statutory auditor)
2 facts ▸
  • General meeting, 27/05/2014
  • Auditor appointment, SCRL Klynveld Peat Marwick Goerdeler - Réviseurs d'entreprise (KPMG) (statutory auditor)
01-04
State Gazette act Resignations & appointments
Power of attorney7 facts ▸
  • Board meeting, 21/02/2014
  • Power of attorney, Alain Bovée
  • Power of attorney, Jorgen Schaffers
  • Power of attorney, Dominique Winand
  • Power of attorney, Catherine Pélissier
  • Power of attorney, Jorgen Schaffers
  • Power of attorney, Dominique Winand
27-01
State Gazette act Miscellaneous
Share transfer1 fact ▸
  • Share transfer, Pfizer International Markets Coöperatief UA
2013
28-11
State Gazette act Capital & shares
Approval2 facts ▸
  • General meeting, 07/11/2013
  • Approval, 07/11/2013
26-11
State Gazette act Miscellaneous
Share acquisition1 fact ▸
  • Share acquisition, Pfizer International Markets Coöperatief UA becomes sole shareholder, 149.271
06-11
State Gazette act Capital & shares
Share transfer · Share cancellation · Capital6 facts ▸
  • General meeting, 08/10/2013
  • Share transfer, AHP Holdings B.V. → Pfizer
  • Share cancellation, 29388, imputation des réserves taxées/bénéfices non distribués antérieurement
  • Capital
  • Statutes amendment
  • Power of attorney, Laurence Einsweiler
22-10
State Gazette act Appointment: SCRL KLYNVELD PEAT MARWICK GOERDELER-Réviseurs d'Entrepríse (KPMG) (statutory auditor)
2 facts ▸
  • General meeting, 15/05/2013
  • Auditor appointment, SCRL KLYNVELD PEAT MARWICK GOERDELER-Réviseurs d'Entrepríse (KPMG) (statutory auditor)
25-09
State Gazette act Resignation: Erik BROUWER (director)
Appointment: Laurence EINSWEILER (director)3 facts ▸
  • General meeting, 29/08/2013
  • Director resignation, Erik BROUWER (director)
  • Director appointment, Laurence EINSWEILER (director)
19-07
State Gazette act Resignations & appointments
Power of attorney · Mandate effective date3 facts ▸
  • Board meeting
  • Power of attorney, Hugues Botman (hr mos region lead belux)
  • Mandate effective date, 01/07/2013
2012
16-05
State Gazette act Appointment: Karel VAN DE SOMPEL (managing director)
2 facts ▸
  • Board meeting, 25/04/2012
  • Director appointment, Karel VAN DE SOMPEL (managing director)
26-04
State Gazette act Resignation: Kristiaan J. WESTELINCK (managing director and director)
Appointment: Didier VINEL (director) · Accounting effect4 facts ▸
  • General meeting, 30/03/2012
  • Accounting effect, 01/04/2012
  • Director resignation, Kristiaan J. WESTELINCK (managing director and director)
  • Director appointment, Didier VINEL (director)
03-04
State Gazette act Resignation: Etienne CATTHOOR (director)
Appointment: Karel VAN DE SOMPEL (director) · Accounting effect · Mandate compensation5 facts ▸
  • General meeting, 05/03/2012
  • Accounting effect, 01/03/2012
  • Director resignation, Etienne CATTHOOR (director)
  • Director appointment, Karel VAN DE SOMPEL (director)
  • Mandate compensation, Karel VAN DE SOMPEL
30-03
State Gazette act Purpose
Purpose change2 facts ▸
  • General meeting, 29/02/2012
  • Purpose change, La Société a également pour objet la fourniture aux professionnels de la santé de conseils et de prestations de services de quelque nature que ce soit dans les…
2011
05-12
State Gazette act Resignations & appointments
Power of attorney5 facts ▸
  • Board meeting, 18/08/2011
  • Power of attorney, Laurence Einsweiler
  • Power of attorney, Alain Bovée
  • Power of attorney, Jorgen Schaffers
  • Power of attorney, Dominique Winand
09-11
State Gazette act Appointment: Erik BROUWER (director)
Mandate compensation3 facts ▸
  • General meeting, 27/09/2011
  • Director appointment, Erik BROUWER (director)
  • Mandate compensation, Erik BROUWER
2010
27-07
State Gazette act Capital & shares · Statutes amendment · Resignations & appointments · Restructuring
Merger · Accounting effect · Capital increase14 facts ▸
  • General meeting, 30/06/2010
  • Merger
  • Accounting effect, 01/12/2009
  • Capital increase, €7.138.000
  • Share issue, nouvelles actions sans valeur nominale, entièrement libérées
  • Share transfer, Pfizer → AHP Holdings B.V.
  • Share transfer, Pfizer → A.H. Robins International Company
  • Capital, €45.914.455
  • Statutes amendment
  • Power of attorney, Nicolas Joseph Thomas BAYERS
  • Power of attorney, Nicolas Joseph Thomas BAYERS
  • Exchange ratio, 1 nouvelle action de la Société Absorbante contre remise de 10,14 actions de la Société Absorbée
  • +2 further facts in this act
27-07
State Gazette act Resignations & appointments
Power of attorney3 facts ▸
  • Board meeting, 01/06/2010
  • Power of attorney, Eva Lauwers
  • Power of attorney, Anne De Backer (hr mos lead)
23-07
State Gazette act Appointment: Arnaud Conan (daily management delegate)
Power of attorney3 facts ▸
  • Board meeting, 06/07/2010
  • Power of attorney, Eva Lauwers
  • Director appointment, Arnaud Conan (daily management delegate)
16-06
State Gazette act Appointment: SCRL Klynveld Peat Marwick Goerdeler - Réviseurs d'entreprises (KPMG) (statutory auditor)
2 facts ▸
  • General meeting, 19/05/2010
  • Auditor appointment, SCRL Klynveld Peat Marwick Goerdeler - Réviseurs d'entreprises (KPMG) (statutory auditor)
27-05
State Gazette act Restructuring
Merger1 fact ▸
  • Merger, 11/05/2010
2008
04-06
State Gazette act Resignation: Cornelis J. Heiman (director)
Appointment: Koenraad Bostoen (director) · Mandate compensation4 facts ▸
  • General meeting, 31/03/2008
  • Director resignation, Cornelis J. Heiman (director)
  • Director appointment, Koenraad Bostoen (director)
  • Mandate compensation, Koenraad Bostoen
04-06
State Gazette act Resignation: Cornelis J Heiman (managing director)
Appointment: Koenraad Bostoen (managing director)4 facts ▸
  • Board meeting, 08/04/2008
  • Director resignation, Cornelis J Heiman (managing director)
  • Director appointment, Koenraad Bostoen (managing director)
  • Director appointment, Koenraad Bostoen (day-to-day manager)
2005
12-07
State Gazette act Capital & shares · Statutes amendment · Miscellaneous
Registered-office move4 facts ▸
  • General meeting, 08/06/2005
  • Registered-office move, 1050 Bruxelles, Boulevard de la Plaine 17
  • Statutes amendment
  • Statutes amendment
2004
13-07
State Gazette act Appointments: KPMG Reviseurs d'Entreprises (statutory auditor) and Georges Weissgerber (director)
Permanent representative: P. Simons · Resignation: Philippe De Backer (director) · Mandate compensation6 facts ▸
  • General meeting, 19/05/2004
  • Auditor appointment, KPMG Reviseurs d'Entreprises (statutory auditor)
  • Permanent representative, P. Simons
  • Director appointment, Georges Weissgerber (director)
  • Director resignation, Philippe De Backer (director)
  • Mandate compensation, PFIZER
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
53 of 54 acts read
About the unread acts

Of the 54 Belgian State Gazette acts we know for this company, 53 have been read. The other one has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
3 directors, 1 in day-to-day management, last change in 2026

Board 3

Laurence Einsweiler
Director · since 01-09-2013
Current
Réginald Decraene
Director · since 01-12-2025
Current
Kathleen Commers
Director · since 01-07-2026
Current
3 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
Georges Weissgerber
Director · since 01-06-2004
Not recently confirmed
Koenraad Bostoen
Director · since 01-04-2008
Not recently confirmed
Laurence Einweller
Director · since 15-05-2019
Not recently confirmed

Day-to-day management 1

Réginald Decraene
Managing director · since 01-12-2025
Current
2 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
Koenraad Bostoen
Managing director · since 04-06-2008
Not recently confirmed
Arnaud Conan
Daily management delegate · since 01-07-2010
Not recently confirmed
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ. See the function holders in the CBE →
Not every act has been read: a resignation may be missing here
1 of this company's 54 Belgian State Gazette acts has not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Elsene · 3 establishment units since 2002
seat establishment All 3 establishment units on the map
Ground area
17.7 ha
Building footprint
3.4 ha
Volume, LiDAR
649,702 m³
3 parcels, Brussels, Flanders · tallest building 57.1 m, ±8 floors. Linked by address, not a title deed.
8 companies at this address See who is registered here
3 establishment units
PFIZER
Lennikse Baan 808, 1070 AnderlechtManufacture of basic metals
since 20022.105.014.717
PFIZER
Pleinlaan 17, 1050 ElseneNACE 51460
since 20022.105.014.816
PFIZER
Salvatorstraat 20, 3500 HasseltManufacture of basic pharmaceutical products and pharmaceutical preparations
since 20192.284.217.564
3 parcels
Flanders 1 (33.3%) Brussels 2 (66.7%)
Parcel (capakey) Region Area Buildings Height / fl.
21307E0036/00S004 Brussels 11.3 ha 1 · 2.3 ha 57.1 m · 5 fl.
71324E0490/00D002 Flanders 5.7 ha 1 · 9,438 m² 29.9 m · 5 fl.
21445C0281/00S008 Brussels 6,782 m² 1 · 1,582 m² 37.0 m · 8 fl.
Linked by address, not proof of ownership
Good to know
3 of 3 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Mandate history

20 people since 2004, 7 in office
Show
  • Board
  • Day-to-day management
  • Statutory auditor
  • not recently confirmed
  • began earlier
Mandates per person, with start and end dates
Name Functions and periods
Laurence Einsweiler
  • Director, from 01-09-2013 to date
Réginald Decraene
  • Director, from 01-12-2025 to date
  • Managing director, from 01-12-2025 to date
Kathleen Commers
  • Director, from 01-07-2026 to date
Georges Weissgerber
  • Director, from 01-06-2004 not ended, last confirmed 13-07-2004
Koenraad Bostoen
  • Director, from 01-04-2008 not ended, last confirmed 04-06-2008
  • Managing director, from 04-06-2008 not ended, last confirmed 04-06-2008
Laurence Einweller
  • Director, already before 15-05-2019 not ended, last confirmed 18-06-2019
Arnaud Conan
  • Daily management delegate, from 01-07-2010 not ended, last confirmed 23-07-2010
Anne De Backer
  • Director, from 18-05-2021 to 01-07-2026
Guy Van den Meersche
  • Director, from 18-05-2021 to 01-07-2026
David Lepoittevin
  • Director, from 01-02-2025 to 01-12-2025
  • Managing director, from 01-02-2025 to 01-12-2025
An Van Gerven
  • Director, from 01-09-2022 ended, last mentioned 06-12-2022
  • Managing director, from 01-09-2022 to 17-10-2024
  • Délégation de la gestion journalière, until 17-10-2024
Karel Van De Sompel
  • Director, from 01-03-2012 to 01-09-2022
  • Managing director, from 01-04-2012 to 01-09-2022
Didier Vinel
  • Director, from 01-04-2012 to 18-05-2021
  • Director, until 18-05-2021
SCRL Klynveld Peat Marwick Goerdeler - Réviseurs d'entreprise (KPMG)
  • Statutory auditor, from 16-06-2010 to 27-06-2016
Erik BROUWER
  • Director, from 27-09-2011 to 25-09-2013
Kristiaan J. WESTELINCK
  • Managing director and director, until 01-04-2012
  • Managing director and director, until 01-04-2012
Etienne CATTHOOR
  • Director, until 01-03-2012
KPMG Réviseurs d'Entreprises
  • Statutory auditor, from 13-07-2004 to 16-06-2010
Cornelis J. Heiman
  • Director, until 31-05-2008
  • Managing director, until 31-05-2008
Philippe De Backer
  • Director, until 01-06-2004
See the board, name and seat on a given date →

Articles of association

Purpose
La société a pour objet la fabrication et le commerce sous toutes ses formes, en ce y compris la représentation, l'importation et l'exportation de substances et de produits…
Full purpose

La société a pour objet la fabrication et le commerce sous toutes ses formes, en ce y compris la représentation, l'importation et l'exportation de substances et de produits pharmaceutiques, chimiques et biochimiques de toute nature, en ce compris des aliments spéciaux pour animaux, de colorants alimentaires et d'autres produits à usage alimentaire, ainsi que tous produits cosmétiques, de toilette et d'hygiène, sous quelque forme que ce soit, des parfums et autres produits similaires ou intervenant dans la fabrication des produits précités. La Société a également pour objet la fourniture aux professionnels de la santé de conseils et de prestations de services de quelque nature que ce soit dans les domaines pouvant se rattacher directement ou indirectement aux soins de santé en général; Elle peut faire toutes opérations commerciales, industrielles, financières, mobilières ou immobilières se rapportant directement ou indirectement, en tout ou en partie, à son objet, ou qui seraient de nature à en faciliter ou à en développer la réalisation. Elle pourra s'intéresser par voie d'apport, de fusion, de souscription ou de toute autre manière, dans toutes entreprises, associations ou sociétés, dont l'objet serait similaire, analogue, connexe ou simplement utile à la réalisation de tout ou partie de son objet.

Structure & network

Part of the group PFIZER INC. 6 companies Group, risk and exposure

Owners and holdings

1 owner

Chain of control

  1. PFIZER INC.US consolidated
  2. Pfizer

Highest known parent: PFIZER INC. (United States). The sources do not say who stands above it.

Owners 1

Holdings 0

No holding stated in the accounts, acts or LEI register we read.

According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.

Connections & network

2 connected companies
Depth

The connected companies are in the list below.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, scroll to zoom.
Linked via shared directors
HOSPIRA BENELUX
Shared director
→
WYETH LEDERLE VACCINES
Shared director
→

Ownership & control

2 board mandates
Control over this companyparent company per the LEI register1
PFIZER INC.
Wilmington, United States
controls
PfizerBE 0401.994.823

Acquisitions and mergers

4 transactions
Took over:PF OFG Belgium
BE 0707.924.608merger by absorption · State Gazette act of 19-03-2019 (2 acts) · effective 25-02-2019
BE 0415.965.989State Gazette act of 27-07-2010 (2 acts)
BE 0552.558.025State Gazette act of 29-12-2015 · effective 30-11-2015
Split off to:Pfizer PFE Belgium
BE 0552.558.025State Gazette act of 30-12-2014 (2 acts)

Capital and shareholders

Shareholders according to the acts
Share transfer act of 10-07-2019 ↗
  • to Pfizer International Markets B.V.
Share transfer act of 27-01-2014 ↗
  • from Pfizer International Markets Coöperatief UA

The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years
  1. 20-05-2020 Capital increase of 10,750,006.46 EUR · to 39,688,620.47 EUR · 216,166 new shares
  2. 11-03-2020 Capital stated in the act · 50,000,000 EUR
  3. 19-03-2019 Capital increase of 10,666,355 EUR · to 39,604,969.01 EUR · 66,895 new shares
  4. 29-12-2015 Capital reduction of 16,975,840.99 EUR · to 28,938,614.01 EUR
  5. 30-12-2014 Capital reduction of 18,489,777.79 EUR · to 27,424,677.21 EUR
  6. 06-11-2013 Capital stated in the act · 149,271 shares
  7. 27-07-2010 Capital increase of 7,138,000 EUR · to 45,914,455 EUR · 29,399 new shares

Public money · subsidies and aid

European research

1 project
Programmes
Projects
FORTIFY - FRAMEWORK FOR OPTIMIZED REGULATION, TRADE SECRETS, AND INTELLECTUAL PROPERTY IN A FEDERATED EUROPEAN HEALTH DATA SPACE
Horizon Europe · associated partner · 01-05-2026 to 30-04-2029 · FORTIFY

Recognitions · licences · registrations

Food safety, FASFC

1 site
Anderlecht2.105.014.717
1 permission
Toelating · Andere grootkeuken (bereiding - distributie maaltijden) · since 01-09-2011

Legal Entity Identifier

549300Z96Y9UZSGHWS54
live in the LEI register

Similar companies · same sector, comparable size

Of 1,903 companies in sector 46460 we hold annual accounts for 1,117. 126 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPublic limited company
Founded01-02-1954
Fiscal year end30-11
Activities, NACEBEL 2025
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
46460Wholesale of pharmaceutical and medical goods
E-invoicing
Reachable via Peppol
Peppol ID 0208:0401994823
Registered 14-10-2025

Register as of 27 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.